In 2010, GlaxoSmithKline (GSK) suspended a small clinical trial of SRT501, a proprietary form of resveratrol, due to safety concerns, and terminated the study later that year [REF].
Although limited human studies have shown resveratrol is well-tolerated,[REF][REF] one clinical study of Alzheimer's disease patients showed there were side effects from daily intake of up to 2 grams, including nausea, diarrhea and weight loss [REF].